149P Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Year: 2024
Type: article
Study design: Clinical Trial
Abstract: treatment.The primary endpoint was the pathologic complete response (pCR) rate; secondary endpoints included R0 resection rate, overall response rate (ORR), eventfree survival (EFS), disease-free survival (DFS), safety.Results: From November 2023 to June 2024, 15 patients were enrolled and completed neoadjuvant treatment; 2 patients were lost to follow-up, and 5 refused surgery.Among the 8 patients who underwent surgery, 1 (12.5%)achieved pCR, and all achieved R0 resection.Tumor regression grades (TRG) observed were TRG0 in 1 (12.5%),TRG2 in 5 (62.5%), and TRG3 in 2 (25.0%) patients.Of the 13 evaluable patients, 8 (62%) achieved partial response (PR) and 5 (38%) had stable disease (SD).ORR and DCR were 62% (8/13) and 100.0%(13/13), respectively.Treatment-related adverse events (TRAEs) occurred in 100% of patients, but no grade 3-5 TRAEs were observed.Toxicity and post-surgery complications were limited, and surgical feasibility was not impacted.Conclusions: Neoadjuvant adebrelimab combined with chemotherapy, followed by surgery and adjuvant treatment, demonstrated good efficacy and safety in patients with resectable locally advanced AEG, offering a promising treatment option for this patient population. Clinical trial identification: NCT06198465.
Source: Immuno-Oncology Technology
Authors: K. Zhu, X. Hu
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374782